PRTA:NASDAQProthena Corporation plc Analysis

Prothena posted a surprising Q1 2026 adjusted EPS of $0.52, beating the consensus loss estimate of $0.31, driven by a milestone payment that lifted revenue to $51.1 million – a dramatic increase from $2.8 million a year ago. Technical signals are mixed: the 20‑day SMA (≈9.61) sits just below the current price (8.79), while the 50‑day SMA (≈10.15) remains above, indicating a short‑term pull‑back. The RSI is around 37, suggesting the stock is approaching oversold territory, but the MACD histogram is negative and the MACD line sits below its signal, flagging bearish momentum. Risk metrics are elevated, with a 30‑day volatility of over 60% and a beta of 1.43, while the price is hovering near the identified support level of $8.63. Despite a negative trailing PE and a high price‑to‑sales multiple (≈7.9), analysts’ target prices imply a potential upside of more than 140%, pointing to significant undervaluation.